Drug Interactions between Pep-Back Ultra and tirzepatide

Consumer information for this interaction is not currently available.

MONITOR: Additive increases in heart rate may occur when tirzepatide is coadministered with other drugs that can also increase heart rate. The mechanism by which tirzepatide may affect heart rate is unknown. In placebo-controlled trials, treatment with tirzepatide resulted in an average increase in heart rate of 2 to 4 beats per minute (bpm) compared to an average increase of 1 bpm in patients receiving placebo. The incidence of patients who had a change in heart rate of greater than 20 bpm from baseline for 2 or more consecutive visits was 2.1%, 3.8% and 2.9% for tirzepatide 5 mg, 10 mg and 15 mg, respectively, compared with 2.1% for placebo. Episodes of sinus tachycardia, associated with a concomitant increase in heart rate of greater than or equal to 15 bpm from baseline, were reported in 4.3%, 4.6%, 5.9% and 10% of subjects treated with placebo or tirzepatide 5 mg, 10 mg and 15 mg, respectively. For patients enrolled in Japan, the reported frequencies of these episodes were 7% (3/43), 7.1% (3/42), 9.3% (4/43) and 23% (10/43), respectively.

MANAGEMENT: Although the clinical relevance of the effects on heart rate is not currently known, some authorities suggest observing caution when tirzepatide is coadministered with other drugs that can increase heart rate such as those with sympathomimetic or anticholinergic activity. Advise patients of the potential risk of tachycardia and to contact their healthcare provider if it occurs in the absence of a known cause (i.e., at rest).